Prevalence and impact of complications on outcomes in patients hospitalized for oral and oropharyngeal cancer treatment

Department of Developmental Biology, Harvard School of Dental Medicine, Boston, MA 02115, USA.
Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology (Impact Factor: 1.46). 11/2011; 112(5):581-91. DOI: 10.1016/j.tripleo.2011.06.032
Source: PubMed


We studied the association between presence of complications and hospitalization outcomes, including hospital charges, length of stay in hospital, and in-hospital mortality.
The Nationwide Inpatient Sample for 2008 was used. All hospital discharges with a primary diagnosis of oral and oropharyngeal cancers were selected. Presence of complications was determined by using ICD-9-CM codes. The association between the presence of complications and outcomes (hospital charges, length of stay, and in-hospital mortality) was examined by multivariable linear and multivariable logistic regression analyses. The effects of several patient- and hospital-related confounders were adjusted in the regression analyses.
A total of 17,632 hospitalizations were attributed to oral and oropharyngeal cancers. A total of 519 (2.9%) patients died in the hospitals. The total hospitalization charges were close to $1.08 billion. Oral and oropharyngeal cancers accounted for 117,472 hospitalization days (mean length of stay 6.6 days). The overall complication rate was 14.95%. The most frequently present complication was hemorrhagic complications. Among the different complications, septicemia was associated with the worst outcomes. Patients with septicemia were associated with the highest odds for in-hospital mortality (OR = 13.06, 95% CI = 3.81-48.50, P = .0001).
Presence of complications was associated with poor outcomes, such as high in-hospital mortality rates, excess hospitalization charges, and longer length of stay in hospital. Among the different complications, septicemia was associated with the worst outcomes.

14 Reads
  • Source
    • "Loco-regional advanced disease often necessitates primary chemoradiotherapy (+/À selective neck dissection) or primary surgical resection (+/À reconstruction) with postoperative chemo-radiotherapy [6]. Acute and late toxicities are both significant problems for these patients [7] and the possibility of de-escalating treatment intensity provides an opportunity to reduce morbidity from standard treatment protocols. Specifically , it has the potential to reduce gastric tube dependence , osteoradionecrosis, pain, scarring, fibrosis, dysphagia, xerostomia, dental decay, hypothyroidism, carotid stenosis and stroke. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Iatrogenic complications associated with current treatment protocols for oropharyngeal squamous cell carcinoma are noted to cause high rates of acute and chronic morbidity. The aims of this study are to provide an overview of the current de-escalation trials for human papillomavirus positive (HPV+) oropharyngeal carcinoma and to evaluate the evidence supporting improved response to treatment of patients within this viral cohort. This study reviewed all completed or in progress randomised controlled trials (RCTs) assessing clinical interventions for human papillomavirus-associated locally advanced oropharyngeal squamous cell carcinoma. We utilised a validated 'risk of bias' tool to assess study quality. We identified nine RCTs that met the full inclusion criteria for this review (all of which are currently on-going and will report from 2015 onwards). Five RCTs performed a post hoc analysis by HPV status, which allowed meta-analysis of 1130 patients. The data reveal a significant difference in overall survival (hazard ratio (HR) 0.49 [95% confidence interval (CI) 0.35-0.69]), loco-regional failure (HR 0.43 [95% CI 0.17-1.11]) and disease specific survival (0.41 [95% 0.3-0.56]) in favour of the HPV+ category. In considering de-escalation treatment protocols, nine studies are currently ongoing. Our meta-analysis provides strong evidence for an improved prognosis in the viral associated cohort when treated by platinum based chemotherapy in combination with radiotherapy or primary radiotherapy. So far, one trial (with moderate to high risk of bias) suggests a reduced survival outcome for the HPV+ population when using the epidermal growth factor receptor (EGFR) inhibitor cetuximab.
    Full-text · Article · Jul 2014 · European Journal of Cancer
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objectives: Oropharyngeal cancer (OPC) is the sixth most common cancer worldwide. Focus on risk factors, improved diagnostic methods and effective management strategies have made it possible to successfully treat OPC. However, the 5-year survival rate has not improved for several years due to multiple treatment complications, tissue morbidity, loss of function, and diminished quality of life. Survivors are faced with complications like oral mucositis, hyposalivation, osteoradionecrosis, tissue fibrosis, morbidity from jaw resection, disfigurement, and loss of function that further diminish quality of life. The aim of this review is to highlight major complications associated with treatment of OPC via a literature search and review of available options for identification and management of these complications. Data sources: Relevant publications on oral complications of OPC therapy were thoroughly reviewed from the literature published between the years 1988 and 2012. We evaluated reported incidence, prevalence, and risk factors for oral complications of chemotherapy and radiotherapy for OPC. The authors conducted an electronic search using English language databases, namely PubMed Plus, Medline (Pre-Medline and Medline), Cochrane Database of Systematic Reviews (evidence-based medicine), Dentistry & Oral Sciences Source, A ccessScience, Embase, Evidence-Based Medicine Reviews Multifile, Google Scholar, ISI Journal Citation Reports, and Ovid Multi-Database. Conclusion: We identified the most common complications associated with the treatment of oral cancers. Based on the information gathered, there is evidence that survival of OPC extends beyond eradication of the diseased tissue. Understanding the potential treatment complications and utilizing available resources to prevent and minimize them are important. Caring for OPC survivors should be a multidisciplinary team approach involving the dentist, oncologist, internist, and social worker to improve the currently stagnant 5-year survival rate of OPC. More emphasis on improved quality of life after elimination of the cancer will ultimately improve OPC survivorship.
    No preview · Article · Feb 2013 · Quintessence international (Berlin, Germany: 1985)
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Objectives: This study examines 9-year discharge patterns and changes in outcomes in oral cancer hospitalizations in the United States. Study design: All hospitalizations with primary diagnosis of oral and oropharyngeal cancers were selected from 2000 to 2008 Nationwide Inpatient Sample. Association between outcomes (in-hospital mortality, length of stay [LOS], hospital charges, and discharge status) and independent variables was examined using multivariable regression analyses. Results: Of 146,928 hospitalizations, 5310 died in hospitals. Mean LOS was 6.7 days. Mean hospitalization charges ranged from $47,331 to $62,885. After adjusting for confounders, in-hospital morality and charges did not vary while LOS decreased. Hospitalizations occurring in 2004-2008 were more likely to be discharged to long-term facilities (odds ratio = 1.24-1.59, P < .05) compared with those in 2000. Conclusion: Our study demonstrates changes in longitudinal trends in socio-demographic and hospital-related factors. Our results do not provide compelling evidence on whether hospitals are saving cost or shifting cost to another type of facility.
    Full-text · Article · Apr 2013
Show more